Neurocrine Gains on Release of Test Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares moved into positive territory Wednesday, on word that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor.Said Chief Medical Officer Eiry Roberts, “Based upon our Phase 1 first-in-human study, we are excited to bring this novel oral…

Tesla Selloff Accelerates On News Of Weak Deliveries

The selloff in Tesla’s (TSLA) stock is worsening after the electric-vehicle maker reported delivery figures for this year’s first quarter that fell far short of Wall Street expectations. Tesla said that it delivered 386,810 vehicles in Q1, down nearly 9% from 423,000 a year earlier.It marks the worst year-over-year decline in the company’s vehicle deliveries ever. Analysts who cover Tesla had expected 425,000 electric vehicle deliveries for the quarter. Even the most pessimistic forecast called for more than 400,000 vehicles to be delivered in Q1. Tesla said that it produced 433,371…